comparemela.com
Home
Live Updates
Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain : comparemela.com
Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain
-- Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population -- -- Company is ramping up patient recruitment by doubling number of countries
Related Keywords
Germany
,
Spain
,
Italy
,
Czech Republic
,
Belgium
,
France
,
Alexander Siebert
,
Ingo Lehrke
,
Claudia Sommer
,
International Association For The Study Of Pain
,
Data Monitoring Committee
,
Trophic Communications
,
Algiax Pharmaceuticals Gmb
,
Algiax Pharmaceuticals
,
Monitoring Committee
,
Chief Executive Officer
,
International Association
,
Pain Intensity Numerical Rating Scale
,
Pharmaceuticals Gmbh
,
Gefallene Big Techs
,
Algiax
,
Pharmaceuticals
,
Nnounces
,
Positive
,
Interim
,
Analysis
,
Hase
,
Study
,
Head
,
Candidate
,
Hronic
,
Neuropathic
,
Rain
,
comparemela.com © 2020. All Rights Reserved.